CAR T cell therapy– FDA safety update
November 28, 2023 - The FDA announced they are investigating the risk of serious risk of T-cell malignancy following BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies.
Download PDF
